GWM
TOVX icon

Geneos Wealth Management’s Theriva Biologics TOVX Stock Holding History

Geneos Wealth Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20
Closed -$2K – 2995
2020
Q3 		$2K Buy
+20
New +$2.67K ﹤0.01% 2452

Other funds holding TOVX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geneos Wealth Management's TOVX Position: Q4 2020 in Review

Geneos Wealth Management sold out of Theriva Biologics (TOVX) in Q4 2020, closing a stake of 20 shares — an estimated $2K sold.

Geneos Wealth Management first reported a position in TOVX in Q3 2020 and held it in 1 quarter. The position peaked at $2K in Q3 2020. 17 funds tracked by Wall St. Rank hold TOVX as of Q4 2020.

  • Geneos Wealth Management reported no remaining Theriva Biologics position as of Q4 2020 after selling out during the quarter.
  • Geneos Wealth Management sold 20 Theriva Biologics shares in Q4 2020, an estimated $2K.
  • Geneos Wealth Management first reported a position in Theriva Biologics in Q3 2020 and held it in 1 quarter.
  • Geneos Wealth Management's Theriva Biologics position peaked at $2K in Q3 2020.
  • 17 funds tracked by Wall St. Rank held Theriva Biologics as of Q4 2020.

Based on Geneos Wealth Management's 13F filing for Q4 2020, filed 19 May 2021.